0.2996

4.50% 0.0129

After Hours: .30 0.0004 +0.13%

Fibrogen Inc (FGEN)

Overview News Price History Option Chain Financials Why FGEN Down? Discussions Forecast

Fibrogen Inc stock is traded at $0.2996, with a volume of 376.98K. It is up +4.50% in the last 24 hours and down -4.89% over the past month. FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Previous Close:

$0.2867

Open:

$0.3

24h Volume:

376.98K

Relative Volume:

0.12

Market Cap:

$29.89M

Revenue:

$147.75M

Net Income/Loss:

$-284.23M

P/E Ratio:

-0.1023

EPS:

-2.93

Net Cash Flow:

$-317.54M

1W Performance:

+1.15%

1M Performance:

-4.89%

6M Performance:

-14.47%

1Y Performance:

-73.72%

1-Day Range:

$0.2874

$0.3024

1-Week Range:

$0.2703

$0.3092

52-Week Range:

$0.18

$1.74

Fibrogen Inc Stock (FGEN) Company Profile

Name

Fibrogen Inc

Sector

Healthcare (1153)

Industry

Biotechnology (665)

Phone

415-978-1200

Address

350 BAY STREET, SAN FRANCISCO, CA

Employee

225

Twitter

@FibroGenInc

Next Earnings Date

2025-03-17

Latest SEC Filings

FGEN's Discussions on Twitter

Compare FGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FGEN Fibrogen Inc	0.2996	29.89M	147.75M	-284.23M	-317.54M	-2.93
VRTX Vertex Pharmaceuticals Inc	490.47	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	585.49	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.87	36.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	236.75	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	252.77	25.74B	3.81B	-644.79M	-669.77M	-6.24

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-02-23	Upgrade	Stifel	Hold → Buy
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy
Sep-22-21	Downgrade	Goldman	Neutral → Sell
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral
Jul-16-21	Downgrade	Stifel	Buy → Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-07-21	Downgrade	Mizuho	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy
Mar-02-21	Downgrade	Jefferies	Buy → Hold
Feb-01-21	Initiated	H.C. Wainwright	Buy
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy
May-01-20	Initiated	Cowen	Market Perform
Apr-27-20	Initiated	BofA/Merrill	Neutral
May-29-19	Resumed	Goldman	Neutral
May-10-19	Downgrade	William Blair	Outperform → Mkt Perform
Apr-12-19	Initiated	Piper Jaffray	Neutral
Feb-11-19	Resumed	Stifel	Buy
Dec-19-18	Upgrade	Citigroup	Neutral → Buy
Aug-08-17	Reiterated	Leerink Partners	Outperform
Aug-08-17	Reiterated	Stifel	Buy
Jul-21-17	Downgrade	Goldman	Buy → Neutral
Jul-11-17	Initiated	Jefferies	Buy
Feb-11-16	Upgrade	Credit Suisse	Neutral → Outperform
Jan-21-16	Initiated	Credit Suisse	Neutral
Dec-04-15	Initiated	Citigroup	Buy
Sep-23-15	Initiated	Lake Street	Hold
Jul-29-15	Initiated	Citigroup	Buy
Jul-20-15	Upgrade	Goldman	Neutral → Buy
Dec-09-14	Initiated	Stifel	Buy

View All

Fibrogen Inc Stock (FGEN) Latest News

Apr 11, 2025

FGEN Stock Price and Chart — NASDAQ:FGEN - TradingView

Apr 11, 2025

Apr 08, 2025

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st

Apr 08, 2025

Apr 02, 2025

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 02, 2025

Apr 01, 2025

William Blair Keeps Their Hold Rating on FibroGen (FGEN) - The Globe and Mail

Apr 01, 2025

Mar 30, 2025

FibroGen extends merger option deadline with Fortis - Investing.com Australia

Mar 30, 2025

Mar 28, 2025

FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa

Mar 28, 2025

Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail

Mar 28, 2025

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology - The Manila Times

Mar 28, 2025

FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com

Mar 28, 2025

Mar 27, 2025

1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail

Mar 27, 2025

Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia

Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India

Mar 25, 2025

Mar 24, 2025

Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada

Mar 24, 2025

Mar 20, 2025

In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media

Mar 20, 2025

Mar 19, 2025

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025

FibroGen Full Year 2024 Earnings: Beats Expectations - Yahoo

Mar 19, 2025

Mar 18, 2025